Acute phase reaction is a systemic response which usually follows a physiological condition that takes place in the beginning of an inflammatory process. This physiological change usually lasts 1-2 days. However, the systemic acute phase response usually lasts longer. The aim of this systemic response is to restore homeostasis. These events are accompanied by upregulation of some proteins (positive acute phase reactants) and downregulation of others (negative acute phase reactants) during inflammatory reactions. Cardiovascular diseases are accompanied by the elevation of several positive acute phase reactants such as C-reactive protein (CRP), serum amyloid A (SAA), fibrinogen, white blood cell count, secretory nonpancreatic phospholipase 2-II (sPLA2-II), ferritin, and ceruloplasmin. Cardiovascular disease is also accompanied by the reduction of negative acute phase reactants such as albumin, transferrin, transthyretin, retinol-binding protein, antithrombin, and transcortin. In this paper, we will be discussing the biological activity and diagnostic and prognostic values of acute phase reactants with cardiovascular importance. The potential therapeutic targets of these reactants will be also discussed. 1. Introduction Since 1930, investigators began to investigate the distant changes occur away from the original site(s) of inflammatory process. The discovery of C-reactive protein (CRP) by Tillett and Francis [1] opened this door wide. These distant systemic changes have been referred to as acute phase response regardless whether they follow an acute or a chronic inflammatory process. Acute phase responses are divided according to the concentrations of many plasma proteins known as acute phase proteins. Acute phase proteins can be defined as those whose plasma protein concentration increase with inflammatory reaction (positive acute phase proteins). However, negative acute phase proteins are those whose plasma protein concentrations decrease with inflammatory reaction. Interleukin- (IL-) 6 is the major stimulator of the production of most acute-phase proteins. Acute phase proteins predict and/or reflect the intensity of cardiovascular diseases. Cardiovascular diseases are accompanied by the elevation of several positive acute phase reactants such as CRP, serum amyloid A (SAA), fibrinogen, white blood cell count, secretory nonpancreatic phospholipase 2-II (sPLA2-II), ferritin, and ceruloplasmin. Cardiovascular diseases are also accompanied by the reduction of negative acute phase reactants such as albumin, transferrin, transthyretin, retinol-binding
References
[1]
W. S. Tillett and T. Francis, “Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus,” The Journal of Experimental Medicine, vol. 52, pp. 561–567, 1930.
[2]
A. S. Whitehead, G. A. P. Bruns, and A. F. Markham, “Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1,” Science, vol. 221, no. 4605, pp. 69–71, 1983.
[3]
E. B. Oliveira, E. C. Gotschlich, and T. Y. Liu, “Primary structure of human C-reactive protein,” The Journal of Biological Chemistry, vol. 254, no. 2, pp. 489–502, 1979.
[4]
P. A. Kavsak, A. R. MacRae, A. M. Newman et al., “Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure,” Clinical Biochemistry, vol. 40, no. 5-6, pp. 326–329, 2007.
[5]
M. B. Pepys and G. M. Hirschfield, “C-reactive protein: a critical update,” Journal of Clinical Investigation, vol. 111, no. 12, pp. 1805–1812, 2003.
[6]
D. M. Vigushin, M. B. Pepys, and P. N. Hawkins, “Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease,” Journal of Clinical Investigation, vol. 91, no. 4, pp. 1351–1357, 1993.
[7]
H. Yu and N. Rifai, “High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy,” Clinical Biochemistry, vol. 33, no. 8, pp. 601–610, 2000.
[8]
R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.
[9]
T. P. Zwaka, V. Hombach, and J. Torzewski, “C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis,” Circulation, vol. 103, no. 9, pp. 1194–1197, 2001.
[10]
V. Pasceri, J. Chang, J. T. Willerson, and E. T. H. Yeh, “Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs,” Circulation, vol. 103, no. 21, pp. 2531–2534, 2001.
[11]
K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer, “Generation of C-reactive protein and complement components in atherosclerotic plaques,” American Journal of Pathology, vol. 158, no. 3, pp. 1039–1051, 2001.
[12]
B. C. Berk, W. S. Weintraub, and R. W. Alexander, “Elevation of C-reactive protein in “active” coronary artery disease,” American Journal of Cardiology, vol. 65, no. 3, pp. 168–172, 1990.
[13]
E. Braunwald, “Unstable angina: an etiologic approach to management,” Circulation, vol. 98, no. 21, pp. 2219–2222, 1998.
[14]
M. Cesari, B. W. J. H. Penninx, A. B. Newman et al., “Inflammatory markers and onset of cardiovascular events: results from the health ABC study,” Circulation, vol. 108, no. 19, pp. 2317–2322, 2003.
[15]
G. J. Blake and P. M. Ridker, “C-reactive protein and other inflammatory risk markers in acute coronary syndromes,” Journal of the American College of Cardiology, vol. 41, no. 4, supplement, pp. 37S–42S, 2003.
[16]
C. Heeschen, C. W. Hamm, J. Bruemmer, and M. L. Simoons, “Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis,” Journal of the American College of Cardiology, vol. 35, no. 6, pp. 1535–1542, 2000.
[17]
F. C. De Beer, C. R K Hind, K. M. Fox, R. M. Allan, A. Maseri, and M. B. Pepys, “Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction,” British Heart Journal, vol. 47, no. 3, pp. 239–243, 1982.
[18]
K. Pietil?, A. Harmoinen, L. P?yh?nen, M. Koskinen, J. Heikkila, and R. Ruosteenoja, “Intravenous streptokinase treatment and serum C-reactive protein in patients with acute myocardial infarction,” British Heart Journal, vol. 58, no. 3, pp. 225–229, 1987.
[19]
S. Ueda, U. Ikeda, and K. Yamamoto, “C-reactive protein and complement in myocardial infarction and postinfarction heart failure,” European Heart Journal, vol. 18, no. 11, pp. 1834–1837, 1997.
[20]
T. Anzai, T. Yoshikawa, H. Shiraki et al., “C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction,” Circulation, vol. 96, no. 3, pp. 778–784, 1997.
[21]
H. Toss, B. Lindahl, A. Siegbahn, and L. Wallentin, “Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease,” Circulation, vol. 96, no. 12, pp. 4204–4210, 1997.
[22]
S. K. James, P. Armstrong, E. Barnathan et al., “Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a. GUSTO-IV Substudy,” Journal of the American College of Cardiology, vol. 41, no. 6, pp. 916–924, 2003.
[23]
B. Lindahl, H. Toss, A. Siegbahn, P. Venge, and L. Wallentin, “Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease,” The New England Journal of Medicine, vol. 343, no. 16, pp. 1139–1147, 2000.
[24]
S. K. James, B. Lindahl, A. Siegbahn et al., “N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy,” Circulation, vol. 108, no. 3, pp. 275–281, 2003.
[25]
M. Suleiman, R. Khatib, Y. Agmon et al., “Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction: predictive role of C-reactive protein,” Journal of the American College of Cardiology, vol. 47, no. 5, pp. 962–968, 2006.
[26]
C. Mueller, H. J. Buettner, J. M. Hodgson et al., “Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients,” Circulation, vol. 105, no. 12, pp. 1412–1415, 2002.
[27]
P. M. Ridker, “Clinical application of C-reactive protein for cardiovascular disease detection and prevention,” Circulation, vol. 107, no. 3, pp. 363–369, 2003.
[28]
M. B. Pepys, “C-reactive protein fifty years on,” The Lancet, vol. 1, no. 8221, pp. 653–657, 1981.
[29]
P. M. Ridker, “High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention,” The American journal of cardiology, vol. 92, no. 4 B, 2003.
[30]
R. S. Schwartz, A. Bayes-Genis, J. R. Lesser, M. Sangiorgi, T. D. Henry, and C. A. Conover, “Detecting vulnerable plaque using peripheral blood: inflammatory and cellular markers,” Journal of Interventional Cardiology, vol. 16, no. 3, pp. 231–242, 2003.
[31]
E. M. Balk, J. Lau, L. C. Goudas et al., “Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review,” Annals of Internal Medicine, vol. 139, no. 8, pp. 670–682, 2003.
[32]
T. A. Pearson, G. A. Mensah, R. W. Alexander et al., “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association,” Circulation, vol. 107, no. 3, pp. 499–511, 2003.
[33]
A. Festa, A. J. G. Hanley, R. P. Tracy, R. D'Agostino, and S. M. Haffner, “Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion,” Circulation, vol. 108, no. 15, pp. 1822–1830, 2003.
[34]
T. B. Ledue, D. L. Weiner, J. D. Sipe, S. E. Poulin, M. F. Collins, and N. Rifai, “Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum,” Annals of Clinical Biochemistry, vol. 35, no. 6, pp. 745–753, 1998.
[35]
T. B. Ledue and N. Rifai, “Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment,” Clinical Chemistry, vol. 49, no. 8, pp. 1258–1271, 2003.
[36]
P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men,” The New England Journal of Medicine, vol. 336, no. 14, pp. 973–979, 1997.
[37]
I. S. Ockene, C. E. Matthews, N. Rifai, P. M. Ridker, G. Reed, and E. Stanek, “Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults,” Clinical Chemistry, vol. 47, no. 3, pp. 444–450, 2001.
[38]
L. M. Biasucci, G. Liuzzo, R. L. Grillo et al., “Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability,” Circulation, vol. 99, no. 7, pp. 855–860, 1999.
[39]
I. Kushner, M. L. Broder, and D. Karp, “Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction,” Journal of Clinical Investigation, vol. 61, no. 2, pp. 235–242, 1978.
[40]
K. O. Pietil?, A. P. Harmoinen, J. Jokiniitty, and A. I. Pasternack, “Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment,” European Heart Journal, vol. 17, no. 9, pp. 1345–1349, 1996.
[41]
V. B. Patel, M. A. Robbins, and E. J. Topol, “C-reactive protein: a “golden marker” for inflammation and coronary artery disease,” Cleveland Clinic Journal of Medicine, vol. 68, no. 6, pp. 521–534, 2001.
[42]
W. Koenig, M. Sund, M. Fr?hlich et al., “C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992,” Circulation, vol. 99, no. 2, pp. 237–242, 1999.
[43]
P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” The New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000.
[44]
M. K. Rutter, J. B. Meigs, L. M. Sullivan, R. B. D'Agostino, and P. W. F. Wilson, “C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study,” Circulation, vol. 110, no. 4, pp. 380–385, 2004.
[45]
P. W. F. Wilson, B. H. Nam, M. Pencina, R. B. D'Agostino, E. J. Benjamin, and C. J. O'Donnell, “C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study,” Archives of Internal Medicine, vol. 165, no. 21, pp. 2473–2478, 2005.
[46]
J. J. Li and C. H. Fang, “C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases,” Medical Hypotheses, vol. 62, no. 4, pp. 499–506, 2004.
[47]
L. J. Powell, “C-reactive protein—a review,” The American journal of medical technology, vol. 45, no. 2, pp. 138–142, 1979.
[48]
K. Matsushita, H. Yatsuya, K. Tamakoshi et al., “High-sensitivity C-reactive protein is quite low in Japanese men at high coronary risk,” Circulation Journal, vol. 71, no. 6, pp. 820–825, 2007.
[49]
M. Kosuge, T. Ebina, T. Ishikawa et al., “Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes,” Circulation Journal, vol. 71, no. 2, pp. 186–190, 2007.
[50]
R. L. Meek, S. Urieli-Shoval, and E. P. Benditt, “Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3186–3190, 1994.
[51]
V. L. King, J. Thompson, and L. R. Tannock, “Serum amyloid A in atherosclerosis,” Current Opinion in Lipidology, vol. 22, no. 4, pp. 302–307, 2011.
[52]
R. Badolato, J. M. Wang, W. J. Murphy et al., “Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes,” Journal of Experimental Medicine, vol. 180, no. 1, pp. 203–209, 1994.
[53]
R. O'Hara, E. P. Murphy, A. S. Whitehead, O. FitzGerald, and B. Bresnihan, “Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1788–1799, 2004.
[54]
C. Song, Y. Shen, E. Yamen et al., “Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes,” Atherosclerosis, vol. 202, no. 2, pp. 596–604, 2009.
[55]
H. Cai, C. Song, I. Endoh et al., “Serum amyloid A induces monocyte tissue factor,” Journal of Immunology, vol. 178, no. 3, pp. 1852–1860, 2007.
[56]
C. P. J. Maury, “Comparative study of serum amyloid A protein and C-reactive protein in disease,” Clinical Science, vol. 68, no. 2, pp. 233–238, 1985.
[57]
J. Wilkins, J. R. Gallimore, G. A. Tennent et al., “Rapid automated enzyme immunoassay of serum amyloid A,” Clinical Chemistry, vol. 40, no. 7, pp. 1284–1290, 1994.
[58]
T. Nakayama, S. Sonoda, T. Urano, T. Yamada, and M. Okada, “Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases,” Clinical Chemistry, vol. 39, no. 2, pp. 293–297, 1993.
[59]
J. M. Mayer, M. Raraty, J. Slavin et al., “Serum amyloid A is a better early predictor of severity than C-reactive protein in acute pancreatitis,” British Journal of Surgery, vol. 89, no. 2, pp. 163–171, 2002.
[60]
G. Cunnane, S. Grehan, S. Geoghegan et al., “Serum amyloid A in the assessment of early inflammatory arthritis,” Journal of Rheumatology, vol. 27, no. 1, pp. 58–63, 2000.
[61]
M. T. Casl, G. Bulatovic, P. Orlic, and M. Sabljar-Matovinovic, “The diagnostic capacity of serum amyloid A protein for early recognition of kidney allograft rejection,” Nephrology Dialysis Transplantation, vol. 10, no. 10, pp. 1901–1904, 1995.
[62]
T. Katayama, H. Nakashima, C. Takagi et al., “Prognostic value of serum amyloid a protein in patients with acute myocardial infarction,” Circulation Journal, vol. 69, no. 10, pp. 1186–1191, 2005.
[63]
G. Liuzzo, L. M. Biasucci, J. R. Gallimore et al., “The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina,” The New England Journal of Medicine, vol. 331, no. 7, pp. 417–424, 1994.
[64]
T. W. Meade, W. R. North, R. Chakrabarti, et al., “Haemostatic function and cardiovascular death: early results of a prospective study,” The Lancet, vol. 1, no. 8177, pp. 1050–1053, 1980.
[65]
W. Nieuwenhuizen, “Biochemistry and measurement of fibrinogen,” European Heart Journal, vol. 16, supplement, pp. 6–10, 1995.
[66]
R. F. Doolittle, “Fibrinogen and fibrin,” Scientific American, vol. 245, no. 6, pp. 126–152, 1981.
[67]
J. J. Stec, H. Silbershatz, G. H. Tofler et al., “Association of fibrinogen with cardiovascular risk factors and cardiovascluar disease the Framingham Offspring Population,” Circulation, vol. 102, no. 14, pp. 1634–1638, 2000.
[68]
M. J. Davies, “The contribution of thrombosis to the clinical expression of coronary atherosclerosis,” Thrombosis Research, vol. 82, no. 1, pp. 1–32, 1996.
[69]
M. Eriksson, N. Egberg, S. Wamala, K. Orth-Gomér, M. A. Mittleman, and K. Schenck-Gustafsson, “Relationship between plasma fibrinogen and coronary heart disease in women,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 1, pp. 67–72, 1999.
[70]
S. G. Thompson, J. Kienast, S. D. M. Pyke et al., “Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris,” The New England Journal of Medicine, vol. 332, no. 10, pp. 635–641, 1995.
[71]
R. Fogari, A. Zoppi, G. Marasi, A. Vanasia, and G. Villa, “Associations between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men,” Journal of Cardiovascular Risk, vol. 1, no. 4, pp. 341–345, 1994.
[72]
H. H. Ditschuneit, M. Flechtner-Mors, and G. Adler, “Fibrinogen in obesity before and after weight reduction,” Obesity Research, vol. 3, no. 1, pp. 43–48, 1995.
[73]
J. Heinrich, L. Balleisen, H. Schulte, G. Assmann, and J. Van de Loo, “Fibrinogen and factor VII in the prediction of coronary risk: results from the PROCAM study in healthy men,” Arteriosclerosis and Thrombosis, vol. 14, no. 1, pp. 54–59, 1994.
[74]
E. Vanninen, J. Laitinen, and M. Uusitupa, “Physical activity and fibrinogen concentration in newly diagnosed NIDDM,” Diabetes Care, vol. 17, no. 9, pp. 1031–1038, 1994.
[75]
M. Gil, M. Zarebiński, and J. Adamus, “Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina,” International Journal of Cardiology, vol. 83, no. 1, pp. 43–46, 2002.
[76]
Y. Shi, Y. Wu, C. Bian, W. Zhang, J. Yang, and G. Xu, “Predictive value of plasma fibrinogen levels: in patients admitted for acute coronary syndrome,” Texas Heart Institute Journal, vol. 37, no. 2, pp. 178–183, 2010.
[77]
J. S. Rana, S. M. Boekholdt, P. M. Ridker et al., “Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study,” Journal of Internal Medicine, vol. 262, no. 6, pp. 678–689, 2007.
[78]
C. S. Keefer and W. H. Resnik, “Angina pectoris: a syndrome caused by anoxemia of the myocardium,” Archives of Internal Medicine, vol. 41, pp. 769–807, 1928.
[79]
J. B. Zalokar, J. L. Richard, and J. R. Claude, “Leukocyte count, smoking, and myocardial infarction,” The New England Journal of Medicine, vol. 304, no. 8, pp. 465–468, 1981.
[80]
R. H. Grimm Jr., J. D. Neaton, and W. Ludwig, “Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality,” Journal of the American Medical Association, vol. 254, no. 14, pp. 1932–1937, 1985.
[81]
A. N. Phillips, J. D. Neaton, D. G. Cook, R. H. Grimm, and A. G. Shaper, “Leukocyte count and risk of major coronary heart disease events,” American Journal of Epidemiology, vol. 136, no. 1, pp. 59–70, 1992.
[82]
W. B. Kannel, K. Anderson, and P. W. F. Wilson, “White blood cell count and cardiovascular disease: insights from the Framingham study,” Journal of the American Medical Association, vol. 267, no. 9, pp. 1253–1256, 1992.
[83]
R. F. Gillum, D. D. Ingram, and D. M. Makuc, “White blood cell count, coronary heart disease, and death: the NHANES I epidemiologic follow-up study,” American Heart Journal, vol. 125, no. 3, pp. 855–863, 1993.
[84]
A. R. Folsom, K. K. Wu, W. D. Rosamond, A. R. Sharrett, and L. E. Chambless, “Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study,” Circulation, vol. 96, no. 4, pp. 1102–1108, 1997.
[85]
C. D. Lee, A. R. Folsom, F. J. Nieto, L. E. Chambless, E. Shahar, and D. A. Wolfe, “White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis Risk in Communities Study,” American Journal of Epidemiology, vol. 154, no. 8, pp. 758–764, 2001.
[86]
D. W. Brown, W. H. Giles, and J. B. Croft, “White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort,” Journal of Clinical Epidemiology, vol. 54, no. 3, pp. 316–322, 2001.
[87]
M. Madjid, I. Awan, J. T. Willerson, and S. W. Casscells, “Leukocyte count and coronary heart disease: implications for risk assessment,” Journal of the American College of Cardiology, vol. 44, no. 10, pp. 1945–1956, 2004.
[88]
R. C. Schlant, S. Forman, J. Stamler, and P. L. Canner, “The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project,” Circulation, vol. 66, no. 2, pp. 401–414, 1982.
[89]
R. Hajj-Ali, W. Zareba, R. Ezzeddine, and A. J. Moss, “Relation of the leukocyte count to recurrent cardiac events in stable patients after acute myocardial infarction,” American Journal of Cardiology, vol. 88, no. 11, pp. 1221–1224, 2001.
[90]
G. Schillaci, M. Pirro, G. Pucci et al., “Prognostic value of elevated white blood cell count in hypertension,” American Journal of Hypertension, vol. 20, no. 4, pp. 364–369, 2007.
[91]
R. H. Orakzai, S. H. Orakzai, K. Nasir et al., “Association of white blood cell count with systolic blood pressure within the normotensive range,” Journal of Human Hypertension, vol. 20, no. 5, pp. 341–347, 2006.
[92]
G. D. Friedman, J. V. Selby, and C. P. Quesenberry Jr., “The leukocyte count: a predictor of hypertension,” Journal of Clinical Epidemiology, vol. 43, no. 9, pp. 907–911, 1990.
[93]
O. Kuchel, “The autonomic nervous system and blood pressure regulation in human hypertension,” in Hypertension: Physiopathology and Treatment, J. Genest, O. Kuchal, P. Hamet, and M. Cantin, Eds., pp. 140–160, McGraw- Hill, New York, NY, USA, 2nd edition, 1983.
[94]
S. Umemoto, N. Suzuki, K. Fujii et al., “Eosinophil counts and plasma fibrinogen in patients with vasospastic angina pectoris,” American Journal of Cardiology, vol. 85, no. 6, pp. 715–719, 2000.
[95]
L. M. Biasucci, G. D'Onofrio, G. Liuzzo et al., “Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia,” Journal of the American College of Cardiology, vol. 27, no. 3, pp. 611–616, 1996.
[96]
S. Pontremoli, F. Salamino, B. Sparatore et al., “Enhanced activation of the respiratory burst oxidase in neutrophils from hypertensive patients,” Biochemical and Biophysical Research Communications, vol. 158, no. 3, pp. 966–972, 1989.
[97]
P. S. Tsao, X. L. Ma, and A. M. Lefer, “Activated neutrophils aggravate endothelial dysfunction after reperfusion of the ischemic feline myocardium,” American Heart Journal, vol. 123, no. 6, pp. 1464–1471, 1992.
[98]
T. Siminiak, N. A. Flores, and D. J. Sheridan, “Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury,” European Heart Journal, vol. 16, no. 2, pp. 160–170, 1995.
[99]
E. H. Ohlstein and A. J. Nichols, “Rabbit polymorphonuclear neutrophils elicit endothelium-dependent contraction in vascular smooth muscle,” Circulation Research, vol. 65, no. 4, pp. 917–924, 1989.
[100]
A. R. Whorton, M. E. Montgomery, and R. S. Kent, “Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells,” Journal of Clinical Investigation, vol. 76, no. 1, pp. 295–302, 1985.
[101]
Z. S. Katusic and P. M. Vanhoutte, “Superoxide anion is an endothelium-derived contracting factor,” American Journal of Physiology, vol. 257, no. 1, pp. H33–H37, 1989.
[102]
A. D. Hingorani, J. Cross, R. K. Kharbanda et al., “Acute systemic inflammation impairs endothelium-dependent dilatation in humans,” Circulation, vol. 102, no. 9, pp. 994–999, 2000.
[103]
J. Mehta, J. Dinerman, P. Mehta et al., “Neutrophil function in ishemic heart disease,” Circulation, vol. 79, no. 3, pp. 549–556, 1989.
[104]
I. Ott, F. J. Neumann, M. Gawaz, M. Schmitt, and A. Sch?mig, “Increased neutrophil-platelet adhesion in patients with unstable angina,” Circulation, vol. 94, no. 6, pp. 1239–1246, 1996.
[105]
S. R. Ommen, R. J. Gibbons, D. O. Hodge, and S. P. Thomson, “Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease,” American Journal of Cardiology, vol. 79, no. 6, pp. 812–814, 1997.
[106]
S. Fichtlscherer, M. Kaszkin, S. Breuer, S. Dimmeler, and A. M. Zeiher, “Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease,” Clinical Science, vol. 106, no. 5, pp. 511–517, 2004.
[107]
E. Hurt-Camejo, G. Camejo, H. Peilot, K. ??rni, and P. Kovanen, “Phospholipase A2 in vascular disease,” Circulation Research, vol. 89, no. 4, pp. 298–304, 2001.
[108]
H. W. M. Niessen, P. A. J. Krijnen, C. A. Visser, C. J. L. M. Meijer, and C. E. Hack, “Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?” Cardiovascular Research, vol. 60, no. 1, pp. 68–77, 2003.
[109]
M. Menschikowski, A. Rosner-Schiering, R. Eckey, E. Mueller, R. Koch, and W. Jaross, “Expression of secretory group IIA phospholipase A2 in relation to the presence of microbial agents, macrophage infiltrates, and transcripts of proinflammatory cytokines in human aortic tissues,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 751–762, 2000.
[110]
E. Hurt-Camejo, S. Andersen, R. Standal et al., “Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low-density lipoproteins,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 2, pp. 300–309, 1997.
[111]
M. Romano, E. Romano, S. Bj?rkerud, and E. Hurt-Camejo, “Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 4, pp. 519–525, 1998.
[112]
G. C. Beck, B. A. Yard, J. Schulte et al., “Secreted phospholipases A2 induce the expression of chemokines in microvascular endothelium,” Biochemical and Biophysical Research Communications, vol. 300, no. 3, pp. 731–737, 2003.
[113]
K. Kugiyama, Y. Ota, K. Takazoe et al., “Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease,” Circulation, vol. 100, no. 12, pp. 1280–1284, 1999.
[114]
W. Koenig, C. Y. Vossen, Z. Mallat, H. Brenner, J. Benessiano, and D. Rothenbacher, “Association between type II secretory phospholipase A 2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease,” European Heart Journal, vol. 30, no. 22, pp. 2742–2748, 2009.
[115]
C. Raguenes-Nicol, F. Russo-Marie, G. Domage et al., “Anti-inflammatory mechanism of alminoprofen: action on the phospholipid metabolism pathway,” Biochemical Pharmacology, vol. 57, no. 4, pp. 433–443, 1999.
[116]
M. J. B. M. Vervoordeldonk, I. M. Pineda Torra, A. J. Aarsman, and H. Van Den Bosch, “Aspirin inhibits expression of the interleukin-1β-inducible group II phospholipase A2,” FEBS Letters, vol. 397, no. 1, pp. 108–112, 1996.
[117]
R. Dua and W. Cho, “Inhibition of human secretory class II phospholipase A2 by heparin,” European Journal of Biochemistry, vol. 221, no. 1, pp. 481–490, 1994.
[118]
W. Pruzanski, E. Stefanski, P. Vadas, T. F. McNamara, N. Ramamurthy, and L. M. Golub, “Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2,” Journal of Rheumatology, vol. 25, no. 9, pp. 1807–1812, 1998.
[119]
O. Wiklund, L. Mattsson-Hultén, E. Hurt-Camejo, and J. Oscarsson, “Effects of simvastatin and atorvastatin on inflammation markers in plasma,” Journal of Internal Medicine, vol. 251, no. 4, pp. 338–347, 2002.
[120]
X. Chen, T. O. Scholl, and T. P. Stein, “Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: the Camden study,” Diabetes Care, vol. 29, no. 5, pp. 1077–1082, 2006.
[121]
R. J. Wood, “The iron-heart disease connection: is it dead or just hiding?” Ageing Research Reviews, vol. 3, no. 3, pp. 355–367, 2004.
[122]
M. C. Linder, K. J. Schaffer, M. Hazegh-Azam, C. Y. J. Zhou, T. N. Tran, and G. M. Nagel, “Serum ferritin: does it differ from tissue ferritin?” Journal of Gastroenterology and Hepatology, vol. 11, no. 11, pp. 1033–1036, 1996.
[123]
M. J. Hynes and M. ó Coinceanainn, “Investigation of the release of iron from ferritin by naturally occurring antioxidants,” Journal of Inorganic Biochemistry, vol. 90, no. 1-2, pp. 18–21, 2002.
[124]
K. D. Welch, C. A. Reilly, and S. D. Aust, “The role of cysteine residues in the oxidation of ferritin,” Free Radical Biology and Medicine, vol. 33, no. 3, pp. 399–408, 2002.
[125]
M. Rudeck, T. Volk, N. Sitte, and T. Grüne, “Ferritin oxidation in vitro: implication of iron release and degradation by the 20s proteasome,” IUBMB Life, vol. 49, no. 5, pp. 451–456, 2000.
[126]
T. N. Tran, S. K. Eubanks, K. J. Schaffer, C. Y. J. Zhou, and M. C. Linder, “Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron,” Blood, vol. 90, no. 12, pp. 4979–4986, 1997.
[127]
C. Beerenhout, O. Bekers, J. P. Kooman, F. M. Van Der Sande, and K. M. L. Leunissen, “A comparison between the soluble transferrin receptor, transferrin saturation and serum ferritin as markers of iron state in hemodialysis patients,” Nephron, vol. 92, no. 1, pp. 32–35, 2002.
[128]
M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris, “Elevated C-reactive protein levels in overweight and obese adults,” Journal of the American Medical Association, vol. 282, no. 22, pp. 2131–2135, 1999.
[129]
D. J. Fleming, P. F. Jacques, J. M. Massaro, R. B. D'Agostino Sr., P. W. F. Wilson, and R. J. Wood, “Aspirin intake and the use of serum ferritin as a measure of iron status,” American Journal of Clinical Nutrition, vol. 74, no. 2, pp. 219–226, 2001.
[130]
K. C. Sung, J. H. Kang, and H. S. Shin, “Relationship of Cardiovascular Risk Factors and Serum Ferritin with C-reactive Protein,” Archives of Medical Research, vol. 38, no. 1, pp. 121–125, 2007.
[131]
J. T. Salonen, K. Nyyssonen, H. Korpela, J. Tuomilehto, R. Seppanen, and R. Salonen, “High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men,” Circulation, vol. 86, no. 3, pp. 803–811, 1992.
[132]
S. Kiechl, J. Willeit, G. Egger, W. Poewe, and F. Oberhollenzer, “Body iron stores and the risk of carotid atherosclerosis: prospective results from the bruneck study,” Circulation, vol. 96, no. 10, pp. 3300–3307, 1997.
[133]
P. Galan, N. Noisette, C. Estaquio et al., “Serum ferritin, cardiovascular risk factors and ischaemic heart diseases: a prospective analysis in the SU.VI.MAX (SUpplementation en VItamines et Minéraux AntioXydants) cohort,” Public Health Nutrition, vol. 9, no. 1, pp. 70–74, 2006.
[134]
C. T. Sempos, A. C. Looker, R. F. Gillum, D. L. McGee, C. V. Vuong, and C. L. Johnson, “Serum ferritin and death from all causes and cardiovascular disease: the NHANES II mortality study,” Annals of Epidemiology, vol. 10, no. 7, pp. 441–448, 2000.
[135]
A. Dominguez-Rodriguez, Tome M. Carrillo-Perez, C. Hernandez-Garcia, et al., “Serum ferritin and acute coronary syndrome: a strong prognostic factor?” International Journal of Cardiology, vol. 152, no. 1, pp. 129–130, 2011.
[136]
Y. Fan, J. Wang, L. Wei, B. He, C. Wang, and Binyao Wang, “Iron deficiency activates pro-inflammatory signaling in macrophages and foam cells via the p38 MAPK-NF-κB pathway,” International Journal of Cardiology, vol. 152, no. 1, pp. 49–55, 2010.
[137]
H. L. Viener and A. P. Levy, “Haptoglobin genotype and the iron hypothesis of atherosclerosis,” Atherosclerosis, vol. 216, no. 1, pp. 17–18, 2011.
[138]
B. H. Bowman and A. Kurosky, “Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation,” Advances in Human Genetics, vol. 12, pp. 189–453, 1982.
[139]
A. P. Levy, R. Asleh, S. Blum et al., “Haptoglobin: basic and clinical aspects,” Antioxidants and Redox Signaling, vol. 12, no. 2, pp. 293–304, 2010.
[140]
M. Kristiansen, J. H. Graversen, C. Jacobsen et al., “Identification of the haemoglobin scavenger receptor,” Nature, vol. 409, no. 6817, pp. 198–201, 2001.
[141]
J. H. Graversen, M. Madsen, and S. K. Moestrup, “CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma,” International Journal of Biochemistry and Cell Biology, vol. 34, no. 4, pp. 309–314, 2002.
[142]
R. Asleh, J. Guetta, S. Kalet-Litman, R. Miller-Lotan, and A. P. Levy, “Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo,” Circulation Research, vol. 96, no. 4, pp. 435–441, 2005.
[143]
F. S. Boretti, P. W. Buehler, F. D'Agnillo et al., “Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs,” Journal of Clinical Investigation, vol. 119, no. 8, pp. 2271–2280, 2009.
[144]
J. H. Crawford, T. S. Isbell, Z. Huang et al., “Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation,” Blood, vol. 107, no. 2, pp. 566–574, 2006.
[145]
G. J. Kato, “Haptoglobin halts hemoglobin's havoc,” Journal of Clinical Investigation, vol. 119, no. 8, pp. 2140–2142, 2009.
[146]
S. Blum, M. Vardi, J. B. Brown et al., “Vitamin e reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype,” Pharmacogenomics, vol. 11, no. 5, pp. 675–684, 2010.
[147]
A. P. Levy, I. Hochberg, K. Jablonski et al., “Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study,” Journal of the American College of Cardiology, vol. 40, no. 11, pp. 1984–1990, 2002.
[148]
A. Roguin, W. Koch, A. Kastrati, D. Aronson, A. Schomig, and A. P. Levy, “Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes,” Diabetes Care, vol. 26, no. 9, pp. 2628–2631, 2003.
[149]
M. Suleiman, D. Aronson, R. Asleh et al., “Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction,” Diabetes, vol. 54, no. 9, pp. 2802–2806, 2005.
[150]
U. Milman, S. Blum, C. Shapira et al., “Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 2, pp. 341–347, 2008.
[151]
T. Costacou, R. E. Ferrell, and T. J. Orchard, “Haptoglobin genotype a determinant of cardiovascular complication risk in type 1 diabetes,” Diabetes, vol. 57, no. 6, pp. 1702–1706, 2008.
[152]
A. P. Levy, I. Hochberg, K. Jablonski et al., “Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study,” Journal of the American College of Cardiology, vol. 40, no. 11, pp. 1984–1990, 2002.
[153]
F. M. Nakhoul, R. Zoabi, Y. Kanter et al., “Haptoglobin phenotype and diabetic nephropathy,” Diabetologia, vol. 44, no. 5, pp. 602–604, 2001.
[154]
A. Roguin, I. Hochberg, E. Nikolsky et al., “Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty,” American Journal of Cardiology, vol. 87, no. 3, pp. 330–332, 2001.
[155]
D. D. Bacquer, G. Backer, M. D. Langlois, J. Delanghe, H. Kesteloot, and M. Kornitzer, “Haptoglobin polymorphism as a risk factor for coronary heart disease mortality,” Atherosclerosis, vol. 157, no. 1, pp. 161–166, 2001.
[156]
P. L. Fox, B. Mazumder, E. Ehernwal, et al., “Ceruplasmin and cardiovascular disease,” Free Radical Biology & Medicine, vol. 28, no. 12, pp. 1735–1744, 2000.
[157]
L. Rydén, “Ceruloplasmin,” in Copper Proteins and Copper Enzymes, Volume III, R. Lontie, Ed., pp. 37–100, CRC Press, Boca Raton, Fla, USA, 1984.
[158]
P. L. Fox, C. Mukhopadhyay, and E. Ehrenwald, “Structure, oxidant activity, and cardiovascular mechanisms of human ceruloplasmin,” Life Sciences, vol. 56, no. 21, pp. 1749–1758, 1995.
[159]
E. Frieden and H. S. Hsieh, “The biological role of ceruloplasmin and its oxidase activity,” Advances in Experimental Medicine and Biology, vol. 74, pp. 505–529, 1976.
[160]
W. H. Tang, Y. Wu, S. J. Nicholls, and S. L. Hazen, “Serum Cp: independently predicts cardiovascular risk in stable cardiac patients,” Circulation, vol. 122, 2010, Meeting Abstract Supplement, abstract no. 18791.
[161]
S. J. Adelstein, T. L. Coombs, and B. L. Vallee, “Metalloenzymes and myocardial infarction. I. The relation between serum copper and ceruloplasmin and its catalytic activity,” The New England Journal of Medicine, vol. 255, no. 3, pp. 105–109, 1956.
[162]
J. Bustamante, M. C. Martin, and J. Fernandez, “Zinc, copper and ceruloplasmin in arteriosclerosis,” Biomedicine Express, vol. 25, no. 7, pp. 244–245, 1976.
[163]
J. T. Powell, B. R. Muller, and R. M. Greenhalgh, “Acute phase proteins in patients with abdominal aortic aneurysms,” Journal of Cardiovascular Surgery, vol. 28, no. 5, pp. 528–530, 1987.
[164]
N. Jayakumari, V. Ambikakumari, K. G. Balakrishnan, and K. Subramonia Iyer, “Antioxidant status in relation to free radical production during stable and unstable anginal syndromes,” Atherosclerosis, vol. 94, no. 2-3, pp. 183–190, 1992.
[165]
J. J. F. Belch, M. Chopra, S. Hutchison et al., “Free radical pathology in chronic arterial disease,” Free Radical Biology and Medicine, vol. 6, no. 4, pp. 375–378, 1989.
[166]
J. T. Salonen, R. Salonen, H. Korpela, S. Suntioinen, and J. Tuomilehto, “Serum copper and the risk of acute myocardial infarction: a prospective population study in men in Eastern Finland,” American Journal of Epidemiology, vol. 134, no. 3, pp. 268–276, 1991.
[167]
J. T. Salonen, R. Salonen, K. Sepp?nen, M. Kantola, S. Suntioinen, and H. Korpela, “Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis,” British Medical Journal, vol. 302, no. 6779, pp. 756–760, 1991.
[168]
J. Swain and J. M. C. Gutteridge, “Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material,” FEBS Letters, vol. 368, no. 3, pp. 513–515, 1995.
[169]
C. Smith, M. J. Mitchinson, O. I. Aruoma, and B. Halliwell, “Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions,” Biochemical Journal, vol. 286, no. 3, pp. 901–905, 1992.
[170]
A. Ziakas, S. Gavrilidis, E. Souliou et al., “Ceruloplasmin is a better predictor of the long-term prognosis compared with fibrinogen, CRP, and IL-6 in patients with severe unstable angina,” Angiology, vol. 60, no. 1, pp. 50–59, 2009.
[171]
N. Jayakumari, V. Ambikakumari, K. G. Balakrishnan, and K. Subramonia Iyer, “Antioxidant status in relation to free radical production during stable and unstable anginal syndromes,” Atherosclerosis, vol. 94, no. 2-3, pp. 183–190, 1992.
[172]
J. T. Salonen, R. Salonen, K. Seppanen, M. Kantola, S. Suntioinen, and H. Korpela, “Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis,” British Medical Journal, vol. 302, no. 6779, pp. 756–760, 1991.
[173]
M. J. Saraiva, “Transthyretin amyloidosis: a tale of weak interactions,” FEBS Letters, vol. 498, no. 2-3, pp. 201–203, 2001.
[174]
A. Mezzetti, M. D. Guglielmi, S. D. Pierdomenico et al., “Increased systemic oxidative stress after elective endarterectomy—relation to vascular healing and remodeling,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 11, pp. 2659–2665, 1999.
[175]
A. G. Shaper, S. G. Wannamethee, and P. H. Whincup, “Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking,” Journal of Clinical Epidemiology, vol. 57, no. 2, pp. 195–202, 2004.
[176]
L. H. Kuller, R. P. Tracy, J. Shaten, and E. N. Meilahn, “Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study,” American Journal of Epidemiology, vol. 144, no. 6, pp. 537–547, 1996.
[177]
J. Danesh, R. Collins, P. Appleby, and R. Peto, “Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies,” Journal of the American Medical Association, vol. 279, no. 18, pp. 1477–1482, 1998.
[178]
R. F. Gillum, D. D. Ingram, and D. M. Makuc, “Relation between serum albumin concentration and stroke incidence and death: the NHANES I epidemiologic follow-up study,” American Journal of Epidemiology, vol. 140, no. 10, pp. 876–888, 1994.
[179]
P. S. Lim, Y. M. Cheng, and S. M. Yang, “Impairments of the biological properties of serum albumin in patients on haemodialysis,” Nephrology, vol. 12, no. 1, pp. 18–24, 2007.
[180]
M. P. Weijenberg, E. J. M. Feskens, J. H. M. Souverijn, and D. Kromhout, “Serum albumin, coronary heart disease risk, and mortality in an elderly cohort,” Epidemiology, vol. 8, no. 1, pp. 87–92, 1997.
[181]
B. Halliwell and J. M. C. Gutteridge, “The antioxidants of human extracellular fluids,” Archives of Biochemistry and Biophysics, vol. 280, no. 1, pp. 1–8, 1990.
[182]
L. H. Kuller, J. E. Eichner, T. J. Orchard, G. A. Grandits, L. McCallum, and R. P. Tracy, “The relation between serum albumin levels and risk of coronary heart disease in the multiple risk factor intervention trial,” American Journal of Epidemiology, vol. 134, no. 11, pp. 1266–1277, 1991.
[183]
A. Phillips, A. G. Shaper, and P. H. Whincup, “Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes,” The Lancet, vol. 2, no. 8677, pp. 1434–1436, 1989.
[184]
L. Djoussé, K. J. Rothman, L. A. Cupples, D. Levy, and R. C. Ellison, “Serum albumin and risk of myocardial infarction and all-cause mortality in the framingham offspring study,” Circulation, vol. 106, no. 23, pp. 2919–2924, 2002.
[185]
A.T. H?stmark, “Serum albumin and prevalence of coronary heart disease: a population-based, cross sectional study,” Norsk Epidemiologi, vol. 13, no. 1, pp. 107–113, 2003.
[186]
V. Menon, X. Wang, T. Greene et al., “Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease,” American Journal of Kidney Diseases, vol. 42, no. 1, pp. 44–52, 2003.
[187]
D. Docci, R. Bilancioni, A. Buscaroli et al., “Elevated serum levels of C-reactive protein in hemodialysis patients,” Nephron, vol. 56, no. 4, pp. 364–367, 1990.
[188]
A. Fine, “Relevance of C-reactive protein levels in peritoneal dialysis patients,” Kidney International, vol. 61, no. 2, pp. 615–620, 2002.
[189]
M. Haubitz, R. Brunkhorst, E. Wrenger, P. Froese, M. Schulze, and K. M. Koch, “Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy,” Peritoneal Dialysis International, vol. 16, no. 2, pp. 158–162, 1996.
[190]
T. A. Ikizler, R. L. Wingard, J. Harvell, Y. Shyr, and R. M. Hakim, “Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study,” Kidney International, vol. 55, no. 5, pp. 1945–1951, 1999.
[191]
M. M. Avram, N. Mittman, L. Bonomini, J. Chattopadhyay, and P. Fein, “Markers for survival in dialysis: a seven-year prospective study,” American Journal of Kidney Diseases, vol. 26, no. 1, pp. 209–219, 1995.
[192]
R. N. Foley, P. S. Parfrey, J. D. Harnett, G. M. Kent, D. C. Murray, and P. E. Barre, “Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease,” Journal of the American Society of Nephrology, vol. 7, no. 5, pp. 728–736, 1996.
[193]
R. M. Bologa, D. M. Levine, T. S. Parker et al., “Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients,” American Journal of Kidney Diseases, vol. 32, no. 1, pp. 107–114, 1998.
[194]
A. R. Qureshi, A. Alvestrand, A. Danielsson et al., “Factors predicting malnutrition in hemodialysis patients: a cross- sectional study,” Kidney International, vol. 53, no. 3, pp. 773–782, 1998.
[195]
G. A. Kaysen, J. A. Dubin, H. G. Müller, W. E. Mitch, and N. W. Levin, “Levels of α1 acid glycoprotein and ceruloplasmin predict future albumin levels in hemodialysis patients,” Kidney International, vol. 60, no. 6, pp. 2360–2366, 2001.
[196]
S. B. Kim, W. S. Yang, and J. S. Park, “Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients,” Peritoneal Dialysis International, vol. 19, no. 2, supplement, pp. S144–S149, 1999.
[197]
S. Y. Hong and D. H. Yang, “Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome,” Nephron, vol. 69, no. 2, pp. 125–130, 1995.
[198]
W. S. Yang, S. B. Kim, W. K. Min, S. Park, M. S. Lee, and J. S. Park, “Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 10, no. 9, pp. 1668–1671, 1995.
[199]
S. B. Kim, W. S. Yang, S. K. Lee, H. S. Chi, and J. S. Park, “Effect of increasing serum albumin on haemostatic factors synthesized in the liver in CAPD patients,” Nephrology Dialysis Transplantation, vol. 13, no. 8, pp. 2053–2058, 1998.
[200]
P. Stenvinkel, L. Berglund, S. Ericsson, A. Alvestrand, B. Angelin, and M. Eriksson, “Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome,” European Journal of Clinical Investigation, vol. 27, no. 2, pp. 169–177, 1997.
[201]
W. S. Yang, S. B. Kim, W. K. Min, and J. S. Park, “Effect of increasing serum albumin onserum lipoprotein (a) concentration in patients on continuous ambulatory peritoneal dialysis,” American Journal of Kidney Diseases, vol. 30, pp. 507–513, 1997.
[202]
J. H. Baxter, H. C. Goodman, and J. C. Allen, “Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis,” The Journal of Clinical Investigation, vol. 40, pp. 490–498, 1961.
[203]
J. C. Allen, J. H. Baxter, and H. C. Goodman, “Effects of dextran, polyvinylpyrrolidone and gamma globulin on the hyperlipidemia of experimental nephrosis,” The Journal of Clinical Investigation, vol. 40, pp. 499–508, 1961.
[204]
A. Kanfer, D. Kleinknecht, M. Broyer, and F. Josso, “Coagulation studies in 45 cases of nephrotic syndrome without uremia,” Thrombosis et Diathesis Haemorrhagica, vol. 24, no. 3, pp. 562–571, 1970.
[205]
K. J. Kim, W. S. Yang, S. B. Kim, S. K. Lee, and J. S. Park, “Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin,” Peritoneal Dialysis International, vol. 17, no. 2, pp. 157–161, 1997.
[206]
L. R. Pickart and M. M. Thaler, “Free fatty acids and albumin as mediators of thrombin stimulated fibrinogen synthesis,” American Journal of Physiology, vol. 230, no. 4, pp. 996–1002, 1976.
[207]
S. D. Johnson, C. E. Lucas, and S. J. Gerrick, “Altered coagulation after albumin supplements for treatment of oligemic shock,” Archives of Surgery, vol. 114, no. 4, pp. 379–383, 1979.
[208]
S. B. Kim, H. S. Chi, J. S. Park, C. D. Hong, and W. S. Yang, “Effect of increasing serum albumin on plasma D-dimer, von Willebrand factor, and platelet aggregation in CAPD patients,” American Journal of Kidney Diseases, vol. 33, no. 2, pp. 312–317, 1999.
[209]
N. U. Bang, C. W. Trygstad, J. E. Schroeder, R. O. Heidenreich, and B. M. Csiscko, “Enhanced platelet function in glomerular renal disease,” The Journal of Laboratory and Clinical Medicine, vol. 81, no. 5, pp. 651–660, 1973.
[210]
K. A. Jorgensen and E. Stoffersen, “On the inhibitory effect of albumin on platelet aggregation,” Thrombosis Research, vol. 17, no. 1-2, pp. 13–18, 1980.
[211]
S. B. Kim, W. S. Yang, E. S. Kang, W. K. Min, and J. S. Park, “Lipoprotein (a) and Apo A phenotypes in patients with end-stage renal disease,” Peritoneal Dialysis International, vol. 17, pp. 236–242, 1997.
[212]
A. J. Marcus, “Platelet activation,” in Atherosclerosis and Coronary Artery Disease, V. Fuster, R. Ross, and E. J. Topol, Eds., pp. 607–637, Raven, Philadelphia, Pa, USA, 1st edition, 1996.
[213]
N. Yoshida and N. Aoki, “Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome,” Blood, vol. 52, no. 5, pp. 969–977, 1978.
[214]
G. Remuzzi, G. Mecca, D. Marchesi, et al., “Platelet hyperaggregability and the nephrotic syndrome,” Thrombosis Research, vol. 16, no. 3-4, pp. 345–354, 1979.
[215]
A. Schieppati, P. Dodesini, A. Benigni, et al., “The metabolism of arachidonic acid by platelets in nephrotic syndrome,” Kidney International, vol. 25, no. 4, pp. 671–676, 1984.
[216]
Z. Duniec and J. Robak, “Albumin is one of lipoxygenase inhibitors in serum,” Polish Journal of Pharmacology and Pharmacy, vol. 36, no. 5, pp. 465–471, 1984.
[217]
C. G. Groth, “The effect of infused albumin and Rheomacrodex on factors governing the flow properties of the human blood,” Acta Chirurgica Scandinavica, vol. 131, no. 4, pp. 290–297, 1966.
[218]
E. McGinley, G. D. O. Lowe, and M. Boulton Jones, “Blood viscosity and haemostasis in the nephrotic syndrome,” Thrombosis and Haemostasis, vol. 49, no. 3, pp. 155–157, 1983.
[219]
J. A. Joles, N. Willekes-Koolschijn, and H. A. Koomans, “Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine,” Kidney International, vol. 52, no. 3, pp. 761–770, 1997.
[220]
M. Feriani, P. L. Kimmel, J. Kurantsin-Mills, and J. P. Bosch, “Effect of renal replacement therapy on viscosity in end-stage renal disease patients,” American Journal of Kidney Diseases, vol. 19, no. 2, pp. 131–139, 1992.
[221]
M. P. Gordge, A. Patel, R. W. Faint, P. B. Rylance, and G. H. Neild, “Blood hyperviscosity and its relationship to progressive renal failure in patients with diabetic nephropathy,” Diabetic Medicine, vol. 7, no. 10, pp. 880–886, 1990.
[222]
A. Fleck and F. R. Path, “Acute phase response: implications for nutrition and recovery,” Nutrition, vol. 4, no. 2, pp. 109–117, 1988.
[223]
J. Y. Yeun and G. A. Kaysen, “Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients,” American Journal of Kidney Diseases, vol. 30, no. 6, pp. 923–927, 1997.
[224]
A. R. Folsom, J. Ma, J. H. Eckfeldt, F. J. Nieto, P. A. Metcalf, and R. W. Barnes, “Low serum albumin: association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima-media thickness,” Annals of Epidemiology, vol. 5, no. 3, pp. 186–191, 1995.
[225]
C. Rapezzi, C. C. Quarta, L. Riva et al., “Transthyretin-related amyloidoses and the heart: a clinical overview,” Nature Reviews Cardiology, vol. 7, no. 7, pp. 398–408, 2010.
[226]
S. H. Ingbar, “Pre-albumin: a thyroxinebinding protein of human plasma,” Endocrinology, vol. 63, no. 2, pp. 256–259, 1958.
[227]
L. Rask, H. Anundi, and P. A. Peterson, “The primary structure of the human retinol-binding protein,” FEBS Letters, vol. 104, no. 1, pp. 55–58, 1979.
[228]
H. E. Schultze and J. F. Heremans, Molecular Biology of Human Proteins, Elsevier, London, UK, 1966.
[229]
P. W. Dickson, A. R. Aldred, and P. D. Marley, “High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain,” Biochemical and Biophysical Research Communications, vol. 127, no. 3, pp. 890–895, 1985.
[230]
J. Robbins, “Thyroxine-binding proteins,” Progress in Clinical and Biological Research, vol. 5, pp. 331–355, 1976.
[231]
M. D. Benson and J. C. Kincaid, “The molecular biology and clinical features of amyloid neuropathy,” Muscle and Nerve, vol. 36, no. 4, pp. 411–423, 2007.
[232]
P. Westermark, K. Sletten, B. Johansson, and G. G. Cornwell, “Fibril in senile systemic amyloidosis is derived from normal transthyretin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 7, pp. 2843–2845, 1990.
[233]
X. Hou, M. I. Aguilar, and D. H. Small, “Transthyretin and familial amyloidotic polyneuropathy: recent progress in understanding the molecular mechanism of neurodegeneration,” FEBS Journal, vol. 274, no. 7, pp. 1637–1650, 2007.
[234]
Y. Ando, M. Nakamura, and S. Araki, “Transthyretin-related familial amyloidotic polyneuropathy,” Archives of Neurology, vol. 62, no. 7, pp. 1057–1062, 2005.
[235]
P. Westermark, M. D. Benson, J. N. Buxbaum et al., “A primer of amyloid nomenclature,” Amyloid, vol. 14, no. 3, pp. 179–183, 2007.
[236]
R. H. Falk and S. W. Dubrey, “Amyloid heart disease,” Progress in Cardiovascular Diseases, vol. 52, no. 4, pp. 347–361, 2010.
[237]
K. B. Shah, Y. Inoue, and M. R. Mehra, “Amyloidosis and the heart: a comprehensive review,” Archives of Internal Medicine, vol. 166, no. 17, pp. 1805–1813, 2006.
[238]
C. Rapezzi, G. Merlini, C. C. Quarta, et al., “Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types,” Circulation, vol. 120, no. 13, pp. 1203–1212, 2009.
[239]
J. Koyama, P. A. Ray-Sequin, R. Davidoff, and R. H. Falk, “Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis,” American Journal of Cardiology, vol. 89, no. 9, pp. 1067–1071, 2002.
[240]
A. V. Kristen, J. B. Perz, S. O. Schonland et al., “Non-invasive predictors of survival in cardiac amyloidosis,” European Journal of Heart Failure, vol. 9, no. 6-7, pp. 617–624, 2007.
[241]
M. R. Almeida, L. Gales, A. M. Damas, I. Cardoso, and M. J. Saraiva, “Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses,” Current Drug Targets, vol. 4, no. 5, pp. 587–596, 2005.
[242]
T. Mairal, J. Nieto, M. Pinto et al., “Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors,” PLoS ONE, vol. 4, no. 1, article e4124, 2009.
[243]
A. M. Johnson, G. Merlini, J. Sheldon, and K. Ichihara, “Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition—international federation of clinical chemistry and laboratory medicine (IFCC): IFCC scientific division committee on plasma proteins (C-PP),” Clinical Chemistry and Laboratory Medicine, vol. 45, no. 3, pp. 419–426, 2007.
[244]
P. Aisen, “Transferrin, the transferrin receptor, and the uptake of iron by cells,” Metal Ions in Biological Systems, vol. 35, pp. 585–631, 1998.
[245]
M. Ahmed, Detection of in vitro and in vivo oxidative modifications of ferritin and transferrin by mass spectrometry: hereditary hemochromatosis as a model, Ph.D. thesis, 2007.
[246]
M. Thevis, R. R. Ogorzalek Loo, and J. A. Loo, “Mass spectrometric characterization of transferrins and their fragments derived by reduction of disulfide bonds,” Journal of the American Society for Mass Spectrometry, vol. 14, no. 6, pp. 635–647, 2003.
[247]
R. Pakdaman, F. B. Abdallah, and J. M. El Hage Chahine, “Transferrin, is a mixed chelate-protein ternary complex involved in the mechanism of iron uptake by serum-transferrin in vitro?” Journal of Molecular Biology, vol. 293, no. 5, pp. 1273–1284, 1999.
[248]
A. Van Campenhout, C. M. Van Campenhout, A. R. Lagrou, and B. Manuel-Y-Keenoy, “Transferrin modifications and lipid peroxidation: implications in diabetes mellitus,” Free Radical Research, vol. 37, no. 10, pp. 1069–1077, 2003.
[249]
J. K. Brieland and J. C. Fantone, “Ferrous iron release from transferrin by human neutrophil-derived superoxide anion: effect of pH and iron saturation,” Archives of Biochemistry and Biophysics, vol. 284, no. 1, pp. 78–83, 1991.
[250]
M. Kar and A. S. Chakraborti, “Release of iron from haemoglobin—a possible source of free radicals in diabetes mellitus,” Indian Journal of Experimental Biology, vol. 37, no. 2, pp. 190–192, 1999.
[251]
P. Martin, C. Walton, C. Chapman, H. J. Bodansky, and M. H. Stickland, “Increased urinary excretion of transferrin in children with Type 1 diabetes mellitus,” Diabetic Medicine, vol. 7, no. 1, pp. 35–40, 1990.
[252]
M. J. O'Donnell, P. Martin, C. M. Florkowski et al., “Urinary transferrin excretion in Type 1 (insulin-dependent) diabetes mellitus,” Diabetic Medicine, vol. 8, no. 7, pp. 657–661, 1991.
[253]
C. K. Cheung, C. S. Cockram, V. T. F. Yeung, and R. Swaminathan, “Urinary excretion of transferrin by non-insulin-dependent diabetics: a marker for early complications?” Clinical Chemistry, vol. 35, no. 8, pp. 1672–1674, 1989.
[254]
C. P. McCormick, J. C. Konen, and Z. K. Shihabi, “Microtransferrinuria and microalbuminuria: I. In the diabetic human,” Clinical Physiology and Biochemistry, vol. 8, no. 2, pp. 53–58, 1990.
[255]
A. M. Bernard, A. A. Amor, J. Goemaere-Vanneste et al., “Microtransferrinuria is a more sensitive indicator of early glomerular damage in diabetes than microalbuminuria,” Clinical Chemistry, vol. 34, no. 9, pp. 1920–1921, 1988.
[256]
G. Cartei, D. Causarano, and R. Naccarato, “Transferrin behaviour in primary haemochromatosis,” Experientia, vol. 31, no. 3, pp. 373–375, 1975.
[257]
R. G. Batey, P. L. C. Fong, S. Shamir, and S. Sherlock, “A non-transferrin-bound serum iron in idiopathic hemochromatosis,” Digestive Diseases and Sciences, vol. 25, no. 5, pp. 340–346, 1980.